PLEASANTON, Calif. — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer’s and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research. Known for complementing a broad range of NIH-funded research that requires harnessing emerging technologies at scale, NIH CARD will use Chromium Single Cell Multiome to profile the epigenome and whole transcriptome across millions of individual cells from ancestrally diverse brain samples.
“Our goal is to provide researchers with a highly detailed genetic map of the damage caused in neurodegenerative disorders,” said Andrew B. Singleton, Ph.D., NIH CARD director. “The hope is that these maps will help scientists increase their understanding and ultimately develop new and better treatments for these devastating disorders.”
Researchers will analyze more than 1,000 samples across multiple control and diseased human brain regions — such as the brainstem, hippocampus, striatum and cerebellum — to learn more about the cellular changes and underlying regulatory elements associated with neurodegenerative diseases. NIH CARD scientists aim to produce high-quality, standardized and harmonized datasets that can be integrated with other modalities, like long-read DNA sequencing. To date, the team has already processed 400 samples with Chromium Single Cell Multiome and recently acquired Visium CytAssist and Xenium In Situ instruments to explore the use of spatial tools for the multi-region atlas.
“So much of neurodegeneration is a black box, but once you start opening up that black box, you have many new avenues for progress. That’s what single cell analysis does; it brings to light the ground truth of the underlying biology at massive scale and high resolution,” said Ben Hindson, Co-founder, President and Chief Scientific Officer at 10x Genomics. “It’s energizing to see our technologies help the research community build an expansive reference set for neuroscience, which could ultimately lead towards developing better ways to prevent, diagnose, treat and one day cure these devastating diseases.”
The human brain atlas is intended to serve as a neurodegenerative disease reference set that better captures ancestral diversity to enable the translation of genetic risk to biological consequence. The collaboration is expected to produce high quality, standardized data that will be openly available to the global scientific community.
NIH CARD is a collaborative initiative of the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke. This project is funded by the NIA Intramural Research Program (ZIAAG000545). The content of this news release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,””enable,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “see,” “estimate,” “predict,” “potential,” “would,” “likely,” “seek” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s expectations regarding the potential impacts of research conducted using our products. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. The material risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.
Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics, Inc. may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact adverse events may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.
10x Genomics, Inc. uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.